Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
https://doi.org/10.14341/2071-8713-4976
Abstract
Type 2 diabetes is difficult to manage and multiple therapeutic approach are usually needed. Moreover, addition to the initial
treatment of most currently available oral antidiabetic agents increases the risk of hypoglycaemia and causes a weight gain. Dipeptidyl
peptidase-IV inhibitors improve glycaemic control by increasing pancreatic beta cell responsiveness to glucose and suppressing inappropriate
glucagon secretion. This article summarizes the data from randomized clinical trial in which efficacy and safety of vildagliptin were
assessed.
treatment of most currently available oral antidiabetic agents increases the risk of hypoglycaemia and causes a weight gain. Dipeptidyl
peptidase-IV inhibitors improve glycaemic control by increasing pancreatic beta cell responsiveness to glucose and suppressing inappropriate
glucagon secretion. This article summarizes the data from randomized clinical trial in which efficacy and safety of vildagliptin were
assessed.
References
1. www.diabetes.org/diabetes-statistics. Last accessed 07 May 2010. www.worlddiabetesday. org/en/the-campaign/unite-for diabetes/why-diabetes. Last accessed 07 May 2010.
2. Ahren B. Glucagon-like peptide-1 (GLP1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 20, Р. 642-651 (1998).
3. Ahren Bo. Islet G protein-coupled receprots as potential targets for treatment of type 2 diabetes. Nature reviews Drug Discovery 8 (2009), Р. 369-385.
4. Baunck M. Function and Glycaemic control following one-year vildagliptin treatment and after 12-week washout in drug-nave patients with type 2 diabetes and mild hyperglycaemia ADA, Orlando 2010 OP 321.
5. Davidson J. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 Inhibitors // Clinical Journal of Medicine, 2009; V. 76, S28-S38.
6. Dejager S., Razac S., Foley J. Vildagliptin in drug-naive patients with type 2 diabetes: 24 week RCT // Horm. Metab. Res., 2007; 39: Р. 218-223.
7. Dotta F., Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-nave patients with type 2 diabetes mellitus // Diabetes Obes. Metab., 2009 11(5): Р. 506- 516; // Metab. 3, Р. 153-165 (2006).
8. Drucker D. The biology of incretin hormones // Cell. Metab. 3, Р. 153-165 (2006).
9. Druckner D.J. Dipeptidyl Peptidase-4 inhibition and the treatment of Type 2 Diabetes // Diabetes Care. 2007 Jun; 30(6): P. 1335-43.
10. Fonseca V., Schweizer A., Albrecht M. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007 Jun; 50(6): P. 1148-51.
11. Garber A., Schweizer et al. Vildagliptin in combunation with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolindione monotherapy // Diab. Obes. Metab., 2007; 9: Р. 166-174.
12. Goke B., Herbson et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes Horm Metab Res 2008; 40: Р. 892-895.
13. Manucci E., Pala L., Ciani S. et al. Hyperglycaemia increases DPP-IV activity in diabetes mellitus // Diabetologia 48: Р. 1168-1172, 2005.
14. Nathan D., Buse J., Davidson M. et al. (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of American Diabetes Association and the European Association for the Study of Diabetes // Diabetologia (2010) 52: Р. 17-30.
15. Nolan J.J. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia (2010) 53: Р. 1247-1249.
16. Pan C. et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 Diabetes // Diabet. Med., 2008; 25: Р. 435-441.
17. Pi-Suyaer F., Scweizer A., Mills D. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 Diabetes // Diab. Res. Clin. Pract., 2007; 76: Р. 132-138.
18. Ryskjaer J., Deacon C.F. et al. Plasma DPP-IV activity in patients with type 2 diabetes Mellitus correlates positively with HbA1c levels, but is not acutely affected by food intake // Eur. J. of Endocrinology 155: Р. 485-493, 2006.
19. Schernthaner G., Barnett H., Betteridge D.J et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 53: Р. 1258-1269.
20. Schwiezer A., Counturier A. Foley Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-nave type 2 Diabetic patients // Diabetes Med., 2007; 24: Р. 955-961.
21. VilsbШll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus // Diabetologia, 2004; 47(3): Р. 357-366.
Review
For citations:
Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4. Obesity and metabolism. 2010;7(3):3-6. (In Russ.) https://doi.org/10.14341/2071-8713-4976
Views:
453
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
